Rocket Lab (RKLB) Q1 2026 Earnings Transcript

Rocket Lab reported record Q1 2026 revenue of $200.3 million, up 63.5% year over year, with gross margin of 38.2% GAAP and adjusted EBITDA loss narrowing to $11.8 million versus guided losses of $21 million to $27 million. Backlog hit a record $2.2 billion, including 31 launch bookings, a $190 million HASTE order, and the largest contract in company history for five Neutron flights plus three Electrons through 2029. Management also raised its liquidity position to more than $2 billion and guided Q2 revenue to $225 million-$240 million, signaling continued growth despite heavier Neutron and acquisition spending.

Analysis

RKLB is transitioning from a single-vehicle launch story into a vertically integrated defense-and-space platform with multiple self-reinforcing revenue loops. The key second-order effect is that backlog quality is improving faster than headline backlog size suggests: launch contracts now increasingly serve as a wedge into higher-margin subsystem content, while subsystem wins create pull-through demand for launch and future prime work. That should support valuation multiple expansion even if near-term reported gross margin is noisy from mix and acquisition integration.

The market is likely still underestimating how much government demand can de-risk the long-duration Neutron ramp. Management is effectively pre-selling a medium-lift vehicle before flight heritage, which is unusual and implies customers are valuing schedule optionality and strategic positioning more than raw price. If even a modest portion of that manifest converts after first flight, the business likely shifts from “high-growth with burn” to “capital-efficient growth with operating leverage” over the next 12-24 months.

The main risk is not demand; it is execution cadence and capital intensity. Neutron remains the gating item for the rerating, and any slip would expose the stock to a classic pre-revenue launch-program de-rating, especially if the broader small-cap growth tape weakens. A less obvious risk is margin dilution from inorganic expansion: the company is deliberately buying capability, but integration drag could mask underlying operating leverage for several quarters and create a better entry point on any post-close hiccup.

Contrast RKLB with RTX: RTX benefits from Golden Dome participation, but RKLB offers more operating torque if the defense space architecture expands as advertised. The stronger contrarian angle is that the stock may still be too cheaply assigned to launch-only economics, when the real optionality is in becoming a toll collector across spacecraft, propulsion, optics, and mission services. If management keeps converting adjacent subsystems into in-house content, the addressable market expands faster than consensus models are likely to capture.

Key Decisions for Investors

• Go long RKLB on any post-earnings pullback of 8-12% over the next 2-4 weeks; the setup favors buying volatility compression because the next major positive catalyst is Neutron progress, not the quarter itself.
• Structure a long RKLB / short LMT or RTX pair for 3-6 months: RKLB has higher upside torque from backlog conversion and vertical integration, while the primes already discount much of the defense demand backdrop.
• Buy RKLB common with a hedge via out-of-the-money downside puts into the next Neutron milestone window (3-6 months) to isolate upside from execution risk; this is preferable to naked calls given binary timing risk.
• If RKLB rallies hard on backlog headlines alone, fade a portion with a tactical trim above recent highs; the cleaner second entry is after the market sees evidence of Neutron test completion rather than contract announcements.
• For higher risk tolerance, long RKLB Jan-2027 calls financed by selling nearer-dated upside calls after any spike; the thesis is that the rerating happens on first-flight credibility plus margin inflection, not just backlog accumulation.